GLP-1 Agonists Guide: Biomarkers, Genetics & Personalization

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 agonists are injectable or oral medications that mimic glucagon-like peptide-1, a natural hormone regulating appetite, satiety, and blood glucose. Clinical trials show semaglutide users lose 15-22% body weight over 68 weeks, and tirzepatide users achieve 22-28% weight loss over similar periods.

Understanding GLP-1 agonists means grasping not just their mechanism, but how individual factors—genetics, biomarkers, metabolic profile, and medical history—may influence treatment suitability and response. PlexusDx takes a precision-wellness approach, helping patients explore whether genetic insights and biomarker context can support more meaningful conversations with their healthcare providers.

How GLP-1 Agonists Work in the Body

GLP-1 is an incretin hormone released after eating. It signals fullness, slows gastric emptying, and promotes insulin secretion in response to blood glucose. GLP-1 agonists bind to GLP-1 receptors throughout the brain, gut, and pancreas, amplifying these natural signaling pathways.

By enhancing GLP-1 signaling, these medications reduce hunger-driven eating, increase satiety satisfaction, and improve glycemic control. This multi-system effect explains why users often report sustained appetite reduction and stabilized energy levels within weeks of starting therapy.

Clinical Evidence: Weight Loss, Metabolic Health, and Efficacy Comparisons

Robust clinical data support GLP-1 agonist efficacy. Semaglutide (STEP trials) achieved mean weight loss of 15.3-18.4% at higher doses. Tirzepatide (SUMO trials) demonstrated superior efficacy: 22.5% at 10 mg, 24.2% at 15 mg over 72 weeks. Head-to-head trials show tirzepatide generally outperforms semaglutide for weight loss.

Medication Class	Mean Weight Loss %	Study Duration	Key Metabolic Benefit
Semaglutide (1.0 mg)	15.3-18.4%	68 weeks	Reduced cardiovascular events in overweight/obese with prior CVD
Tirzepatide (15 mg)	22.5-24.2%	72 weeks	Superior HbA1c reduction; dual GLP-1/GIP receptor agonism
Semaglutide (low-dose oral)	10-14% (approx)	52 weeks	GI tolerability; convenient daily option
Tirzepatide (oral, emerging)	15-18% (approx)	52 weeks	Ongoing trials; anticipated comparable injectable efficacy

Genetic and Biomarker Factors That May Influence GLP-1 Responsiveness

Individual response to GLP-1 agonists varies. Genetic variants in GLP1R, GIPR, FTO, and MC4R genes influence appetite regulation, insulin sensitivity, and metabolic rate. PlexusDx's Precision Peptide Genetic Test examines key variants in these pathways to reveal predispositions in peptide-related biology.

Biomarkers such as baseline HbA1c, fasting glucose, leptin, GLP-1 baseline levels, and inflammatory markers (CRP, IL-6) may provide context for treatment suitability. Individuals with higher baseline GLP-1 deficiency or inflammatory profiles may show different response patterns. These insights should be interpreted with a qualified healthcare provider to inform personalized decision-making.

Safety, Side Effects, and Who Should Avoid GLP-1 Agonists

Common GLP-1 side effects include nausea, vomiting, diarrhea, and constipation—typically mild to moderate and diminishing over 4-12 weeks. Rare but serious risks include acute pancreatitis, severe hypoglycemia (especially with concurrent diabetes medications), and medullary thyroid carcinoma (in animal studies; human data insufficient). Absolute contraindications include personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

GLP-1 agonists require careful monitoring in pregnancy, severe renal impairment, and acute illness. Dose adjustment is essential when combined with insulin or sulfonylureas. A qualified provider should assess your full medical history, current medications, and metabolic status before initiating therapy to ensure safety and appropriate dosing strategy.

Compounded vs. Branded GLP-1 Options: What Patients Should Know

GLP-1 agonists are available as branded medications (semaglutide in Ozempic, Wegovy; tirzepatide in Mounjaro, Zepbound) and as compounded preparations from licensed 503A pharmacies. Compounded medications contain the same active pharmaceutical ingredients but are prepared by compounding pharmacies under state pharmacy board oversight.

PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B facilities—to provide compounded semaglutide and tirzepatide at lower price points ($149/mo monthly depending on type and dose) compared to branded alternatives. Compounded medications are not FDA-approved but are legal and regulated. Your provider can advise whether compounded or branded options suit your clinical needs and access requirements.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—genes central to appetite regulation and metabolic response. Identifying your genetic predispositions in these pathways may help provide context for how your body's GLP-1 signaling biology is wired, informing more informed conversations with your provider about treatment suitability.

The genetic test reveals predispositions in peptide-related pathways; it does not predict your exact medication response or guarantee outcomes. Genetic variants influence risk and responsiveness, but diet, activity, stress, sleep, and medical status also shape results. These insights should be interpreted with a qualified healthcare provider as one piece of your overall clinical picture.

Combining genetic insights with biomarker assessment (HbA1c, baseline GLP-1 levels, inflammatory markers) and your full medical history can support a more personalized provider conversation about whether GLP-1 agonist therapy is appropriate, which formulation (injectable vs. oral, compounded vs. branded) aligns with your needs, and what dose escalation strategy may optimize both safety and efficacy for your unique biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.